List of Excipients in Branded Drug BRAFTOVI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Array BioPharma Inc	BRAFTOVI	encorafenib	70255-025	CELLULOSE, MICROCRYSTALLINE	2032-11-21
Array BioPharma Inc	BRAFTOVI	encorafenib	70255-025	COPOVIDONE K25-31	2032-11-21
Array BioPharma Inc	BRAFTOVI	encorafenib	70255-025	CROSPOVIDONE	2032-11-21
Array BioPharma Inc	BRAFTOVI	encorafenib	70255-025	FERRIC OXIDE RED	2032-11-21
Array BioPharma Inc	BRAFTOVI	encorafenib	70255-025	FERRIC OXIDE YELLOW	2032-11-21

BRAFTOVI Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

BRAFTOVI (encorafenib) uses a conventional immediate-release hard-capsule platform with a high-value excipient profile built around powder flow, content uniformity, dissolution, and scalable manufacture. The strongest commercial opportunities are in generic and authorized-generic development, excipient substitution, dose-flexible oral products, pediatric or swallowing-friendly formats, and combination packaging with MEKTOVI (binimetinib) or cetuximab-based treatment regimens.

What excipients are used in BRAFTOVI capsules?

BRAFTOVI is an oral capsule containing encorafenib. The FDA-approved product uses a powder-filled hard capsule rather than a modified-release, lipid-based, or amorphous solid-dispersion delivery system.

Public product information identifies the principal capsule-fill excipients as:

Excipient	Likely formulation function
Copovidone	Binder and solubilization aid
Poloxamer 188	Wetting and dissolution support
Microcrystalline cellulose	Diluent and compression or fill-property aid
Colloidal silicon dioxide	Glidant and moisture-control support
Sodium lauryl sulfate	Wetting agent
Magnesium stearate	Lubricant
Gelatin	Capsule shell
Titanium dioxide and approved colorants	Capsule-shell opacity and identification

The exact quantitative composition, particle-size specifications, manufacturing order, and process controls are not generally disclosed in the prescribing information. The FDA label identifies inactive ingredients but does not provide the complete qualitative and quantitative formula. [1][2]

The formulation strategy is consistent with a low-dose, poorly water-soluble small molecule that requires reliable wetting and powder processing. Copovidone, poloxamer 188, and sodium lauryl sulfate provide complementary functions. Microcrystalline cellulose supports bulk density and fill uniformity. Colloidal silicon dioxide improves flow, while magnesium stearate reduces adhesion during capsule manufacture.

Why does BRAFTOVI use a conventional capsule platform?

A hard capsule supports:

• Rapid release without a complex controlled-release mechanism.
• Multiple dose strengths.
• Relatively simple scale-up.
• Lower manufacturing complexity than multiparticulate or osmotic systems.
• Easier replacement of individual excipients during generic development.
• Standard high-speed encapsulation and blister or bottle packaging.

The strategy also fits encorafenib’s clinical use, where dosing is adjusted by indication and by concomitant therapy. BRAFTOVI is approved in combination with binimetinib for BRAF V600E or V600K metastatic melanoma and BRAF V600E metastatic non-small cell lung cancer, and in combination with cetuximab for BRAF V600E metastatic colorectal cancer. [1]

What is the commercial role of each BRAFTOVI excipient?

The largest technical value is concentrated in excipient compatibility and process performance rather than in the individual ingredients.

Copovidone and poloxamer 188

Copovidone can improve powder cohesion and assist drug wetting. Poloxamer 188 can improve surface wetting and dissolution of hydrophobic drug particles. Their use together may help maintain dissolution across changes in particle size, bulk density, and encapsulation conditions.

Potential supplier opportunities include:

• Pharmaceutical-grade copovidone with controlled molecular-weight distribution.
• Low-peroxide poloxamer 188.
• Excipient grades designed for direct filling.
• Excipient combinations that reduce dissolution variability.
• Supply agreements with generic manufacturers and contract development and manufacturing organizations.

Poloxamer quality is commercially important because peroxide formation, residual moisture, and lot-to-lot differences can affect sensitive active pharmaceutical ingredients.

Microcrystalline cellulose and colloidal silicon dioxide

These ingredients support powder handling. For a capsule product, blend uniformity and consistent fill weight are central quality attributes. Microcrystalline cellulose affects bulk density, compressibility, and segregation risk. Colloidal silicon dioxide affects flow and can reduce agglomeration.

Commercial differentiation can come from:

• Co-processed diluents.
• Low-dust silica grades.
• Engineered particle-size distributions.
• Excipient systems optimized for low-dose API blends.
• Continuous-manufacturing-compatible excipient grades.

A substitute formulation must demonstrate equivalent performance, not merely match the labeled inactive ingredients.

Sodium lauryl sulfate

Sodium lauryl sulfate is a powerful surfactant that can improve wetting and dissolution. Its inclusion may create a substitution barrier because changing concentration or replacing it with another surfactant can alter dissolution, gastrointestinal tolerability, and stability.

Possible alternatives include poloxamers, sodium dodecyl sulfate at a different concentration, or other wetting agents. Each substitution would require comparative dissolution, impurity, stability, and bioequivalence work.

Magnesium stearate

Magnesium stearate is a standard lubricant but can create over-lubrication risks. Excessive blending can reduce wettability and slow dissolution. The commercial opportunity is less about replacing magnesium stearate than about optimizing:

• Lubricant concentration.
• Lubrication time.
• Shear exposure.
• Blend order.
• Encapsulation speed.
• Equipment-specific transfer behavior.

What formulation opportunities exist for BRAFTOVI?

The current product leaves several potential development pathways open.

Excipient-substituted generic capsules

The most immediate opportunity is an ANDA product using a different qualitative or quantitative excipient composition. A generic manufacturer may retain the same capsule platform while changing:

• Binder grade.
• Surfactant concentration.
• Diluent ratio.
• Glidant level.
• Lubricant concentration.
• Capsule-shell composition.
• Color system.

The main development target is pharmaceutical equivalence plus bioequivalence. The product must match the reference product’s dosage form, strength, route, and relevant performance characteristics under the FDA abbreviated pathway. [3]

Lactose-free or simplified formulations

A lactose-free product could have commercial value if the reference formulation or a competing generic uses lactose in a particular market presentation. The publicly identified BRAFTOVI excipient list does not make lactose the central formulation component, which reduces the differentiation opportunity in the United States. A simplified formulation may still improve procurement, allergen policies, or regional registration.

Pediatric and swallowing-friendly products

BRAF-targeted therapy is increasingly used across oncology settings, but pediatric formulation opportunities require careful clinical and regulatory assessment. Potential formats include:

• Smaller capsules.
• Lower-strength capsules.
• Sprinkle capsules.
• Oral granules.
• Taste-masked suspension intermediates.
• Capsules that can be opened and dispersed under controlled conditions.

An oral liquid would face substantial stability, dose-uniformity, preservative, and palatability challenges. A sprinkle formulation would need validated administration instructions and evidence that capsule opening does not change exposure or create occupational handling risks.

Fixed-dose combination and co-pack products

A fixed-dose encorafenib/binimetinib product could simplify administration but would face major dose-ratio and stability constraints. The approved regimen uses separate BRAFTOVI and MEKTOVI products, allowing dose adjustment and interruption of one component.

A co-pack or adherence kit is more commercially practical than a fixed-dose combination. Opportunities include:

• BRAFTOVI and MEKTOVI synchronized blister packs.
• Calendarized combination packaging.
• Dose-modification packs.
• Hospital or specialty-pharmacy starter kits.
• Combination packaging aligned with cetuximab treatment cycles.

These products may improve adherence without changing the active formulation.

What patents protect BRAFTOVI’s formulation and use?

BRAFTOVI’s commercial protection is expected to rely primarily on active-ingredient, pharmaceutical-composition, therapeutic-use, and regulatory exclusivity rights rather than on a single excipient patent.

Excipient substitutions generally do not avoid active-ingredient or method-of-use patents if the generic product still contains encorafenib and is labeled for the protected indication. A formulation patent can create a separate barrier when it claims a specific composition, dissolution profile, polymorph, particle-size range, or manufacturing process.

The relevant diligence areas are:

Protection category	Relevance to BRAFTOVI
Encorafenib composition patents	Core small-molecule exclusivity
Pharmaceutical-composition patents	May cover dosage forms or specific excipient combinations
Method-of-use patents	May cover BRAF-mutant melanoma, colorectal cancer, or lung cancer treatment
Combination patents	May cover encorafenib with binimetinib or cetuximab
Manufacturing patents	May restrict process or solid-state production routes
Regulatory exclusivity	Can delay approval even where patent coverage is limited
Trademark rights	Protect BRAFTOVI branding but do not block generic approval

The FDA Orange Book should be reviewed for current listed patents, expiration dates, pediatric extensions, and certifications associated with an ANDA. Patent status can change through terminal disclaimers, patent-term adjustment, litigation, settlements, or delisting. [4]

When does BRAFTOVI lose exclusivity?

BRAFTOVI does not have a single practical loss-of-exclusivity date. Market entry depends on the interaction of:

1. Orange Book-listed patents.
2. Patent-term extensions or adjustments.
3. Regulatory exclusivity.
4. Paragraph IV certifications.
5. Patent litigation and settlement terms.
6. The scope of approved generic labeling.

The original U.S. approval dates were:

Milestone	Date
FDA approval for BRAF-mutant metastatic melanoma with binimetinib	June 27, 2018
FDA approval with cetuximab for BRAF V600E metastatic colorectal cancer	April 8, 2020
FDA approval for BRAF V600E metastatic NSCLC with binimetinib	October 11, 2023

[1][5]

A generic may enter before all method-of-use patents expire if it uses a permitted label carve-out and avoids the protected indication. That strategy is less straightforward for BRAFTOVI because treatment is concentrated in genetically defined oncology populations and the principal commercial regimens involve combination therapy.

What generic entry risks exist for BRAFTOVI?

BRAFTOVI is a small molecule, so the primary threat is conventional generic competition rather than biosimilar competition.

Paragraph IV risk

A Paragraph IV filer could challenge Orange Book-listed patents by asserting that a patent is invalid, unenforceable, or not infringed. Filing an ANDA with a Paragraph IV certification can trigger patent litigation and a potential 30-month stay of approval under the Hatch-Waxman framework. [3]

Potential generic strategies include:

• Full-label ANDA.
• Skinny-label ANDA excluding a patented indication.
• Formulation redesign.
• Alternative solid-state form.
• Alternative manufacturing process.
• Strength-by-strength launch.
• Authorized-generic distribution.

Biosimilar risk

Biosimilars do not directly compete with BRAFTOVI because encorafenib is a chemically synthesized small molecule, not a biologic. The relevant competitive risks are generics, new BRAF/MEK combinations, next-generation targeted therapies, and treatment-sequencing changes.

Commercial launch scenarios

Scenario	Commercial effect
Single generic launch	Moderate price pressure; specialty distribution may limit immediate erosion
Multiple generic entrants	Faster price compression and payer substitution
Skinny-label launch	Partial erosion, concentrated in non-protected indications
Authorized generic	Greater control over price segmentation and channel access
Co-pack or adherence product	Retention strategy for combination therapy
New targeted competitor	Share loss before generic entry through clinical substitution

Which companies are positioned to challenge BRAFTOVI?

Potential challengers include large generic companies with oncology portfolios, specialty generic manufacturers, and contract development organizations that can support low-dose capsule development. The most credible candidates are companies with:

• Oncology ANDA experience.
• Encapsulation and powder-blending capability.
• Strong analytical development groups.
• Access to comparative bioavailability studies.
• Specialty-pharmacy distribution.
• Experience litigating Paragraph IV cases.

Public confirmation of a specific Paragraph IV filer, lawsuit, or settlement should be based on current FDA, PACER, and Orange Book records. A generic company’s product development activity alone does not establish a legal challenge.

How strong is the BRAFTOVI excipient estate?

The excipient estate is strategically useful but unlikely to be the sole source of long-term exclusivity. Its strength depends on whether the reference product is protected by a narrow composition claim or by broader active-ingredient and therapeutic-use claims.

Stronger barriers

• Difficult-to-reproduce dissolution profile.
• Sensitive API-excipient compatibility.
• Narrow bioequivalence operating range.
• Combination-use patents.
• Manufacturing controls that are difficult to reverse-engineer.
• Multiple strengths requiring consistent performance.

Weaker barriers

• Common excipients with widely available pharmaceutical grades.
• Conventional gelatin capsule technology.
• Straightforward immediate-release dissolution.
• Availability of substitute binders, surfactants, and diluents.
• Lack of a complex delivery mechanism.

For excipient suppliers, the commercial value is therefore more likely to arise from formulation know-how, supply reliability, and regulatory support than from ownership of a blocking patent.

What licensing deals affect BRAFTOVI commercialization?

Pfizer acquired Array BioPharma in 2019, bringing encorafenib and binimetinib into Pfizer’s oncology portfolio. BRAFTOVI and MEKTOVI commercialization has also involved regional commercial arrangements, including Pierre Fabre in markets outside the United States. [6]

Licensing and commercialization diligence should examine:

• Geographic rights.
• Responsibility for formulation changes.
• Generic defense obligations.
• Supply and technology-transfer terms.
• Rights to new dosage forms.
• Ownership of improvements.
• Co-pack and combination-product rights.
• Royalty obligations after patent expiry.

Regional rights can produce different excipient and packaging opportunities because capsule-shell materials, colorants, labeling, and excipient acceptability requirements differ across jurisdictions.

What regulatory status does BRAFTOVI have?

BRAFTOVI is FDA-approved as an oral encorafenib capsule. Its principal U.S. uses are combination regimens for BRAF-mutated cancers, including melanoma, colorectal cancer, and non-small cell lung cancer. [1]

For a reformulated or generic product, key regulatory issues include:

• Pharmaceutical equivalence.
• Bioequivalence.
• Comparative dissolution.
• Impurity and degradation control.
• Capsule-shell compatibility.
• Extractables and leachables.
• Stability under commercial packaging.
• Labeling for approved combination regimens.
• Manufacturing controls for low-dose uniformity.

The commercial opportunity is strongest where a developer can reduce manufacturing cost or improve administration without changing the established immediate-release product profile.

Key Takeaways

• BRAFTOVI is a conventional immediate-release hard capsule containing encorafenib.
• The formulation relies on copovidone, poloxamer 188, microcrystalline cellulose, colloidal silicon dioxide, sodium lauryl sulfate, and magnesium stearate.
• The main excipient opportunity is generic formulation development, not a standalone excipient patent strategy.
• Poloxamer, surfactant, binder, and lubricant selection can materially affect dissolution and bioequivalence.
• Pediatric, sprinkle, adherence-pack, and co-pack formats are the most credible differentiated product opportunities.
• BRAFTOVI has small-molecule generic risk, not biosimilar risk.
• Orange Book patents, Paragraph IV filings, litigation, and settlement terms determine the practical launch window.
• Combination use with MEKTOVI and cetuximab increases the value of packaging and adherence solutions.
• Excipient suppliers can compete through controlled grades, technical support, supply security, and regulatory documentation.

FAQs

Can BRAFTOVI capsules be opened and mixed with food?

The FDA-approved labeling should control administration. A generic developer cannot assume that capsule opening or mixing with food is acceptable without supporting stability, dose-uniformity, and exposure data.

Is BRAFTOVI suitable for an oral suspension?

A suspension would require new development work covering solubility, sedimentation, redispersibility, preservative performance, taste, dose uniformity, and stability. It would be a differentiated product rather than a simple generic substitution.

Could a generic replace sodium lauryl sulfate in BRAFTOVI?

Yes, a generic may use a different excipient composition if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and product performance. The replacement would require comparative development data.

Does BRAFTOVI have a fixed-dose combination with MEKTOVI?

BRAFTOVI and MEKTOVI are marketed as separate products. A fixed-dose combination would face dose-ratio, stability, dose-adjustment, and regulatory challenges. A synchronized co-pack is a more practical commercial option.

Which excipient creates the greatest development risk?

Surfactant and binder changes create the greatest risk because they can alter wetting, dissolution, and exposure. Lubricant overuse also can reduce dissolution and produce bioequivalence failures.

References

1. U.S. Food and Drug Administration. (2023). BRAFTOVI (encorafenib) capsules: Prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: BRAFTOVI-encorafenib capsule.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2023, October 11). FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with BRAF V600E mutation.
6. Pfizer Inc. (2019). Pfizer to acquire Array BioPharma.